Advertisement

Recurrent Abdominal Pain

  • Michelle Korah-SedgwickEmail author
Chapter

Abstract

Hereditary angioedema (HAE) is characterized by episodic, recurrent bouts of isolated angioedema

Laboratory diagnosis for types I and II HAE requires a low C4 and low C1 esterase inhibitor (C1-INH) antigenic levels

C4 levels are inherently low in children younger than 12 months of age

The angioedema in HAE and AAE is bradykinin-mediated, not histamine-mediated, and is therefore unresponsive to histamine blockade

Recombinant or plasma-derived C1-INH is first-line treatment for acute HAE attacks

Up to 25% of HAE are due to de novo mutations, hence absence of family history should not delay evaluation for HAE

Keywords

Hereditary angioedema C1 esterase inhibitor Bradykinin 

References

  1. 1.
    Zuraw BL, Bernstein JA, Lang DM, Craig T, Dreyfus D, Hsieh F, Khan D, Sheikh J, Weldon D, Bernstein DI, Blessing-Moore J, Cox L, Nicklas RA, Oppenheimer J, Portnoy JM, Randolph CR, Schuller DE, Spector SL, Tilles SA, Wallace D. A focused parameter update: hereditary angioedema, acquired C1 inhibitor deficiency, and angiotensin-converting enzyme inhibitor-associated angioedema. J Allergy Clin Immunol. 2013;131(6):1491–3.CrossRefGoogle Scholar
  2. 2.
    Agostoni A, Cicardi M. Hereditary and acquired C1-inhibitor deficiency: biological and clinical characteristics in 235 patients. Medicine. 1992;71(4):206–15.CrossRefGoogle Scholar
  3. 3.
    Farkas H. Pediatric hereditary angioedema due to C1-inhibitor deficiency. Allergy Asthma Clin Immunol. 2010;6(1):18.CrossRefGoogle Scholar
  4. 4.
    Nanda MK, Elenburg S, Bernstein JA, Assa'ad AH. Clinical features of pediatric hereditary angioedema. J Allergy Clin Immunol Pract. 2015;3(3):392–5.CrossRefGoogle Scholar
  5. 5.
    Wuillemin WA. Therapeutic agents for hereditary angioedema. N Engl J Med. 2011;364(1):84–5; author reply 5-6.CrossRefGoogle Scholar
  6. 6.
    Bork K, Meng G, Staubach P, Hardt J. Hereditary angioedema: new findings concerning symptoms, affected organs, and course. Am J Med. 2006;119(3):267–74.CrossRefGoogle Scholar
  7. 7.
    Frank MM, Gelfand JA, Atkinson JP. Hereditary angioedema: the clinical syndrome and its management. Ann Intern Med. 1976;84(5):580–93.CrossRefGoogle Scholar
  8. 8.
    Bracho FA. Hereditary angioedema. Curr Opin Hematol. 2005;12(6):493–8.CrossRefGoogle Scholar
  9. 9.
    Longhurst H, Cicardi M. Hereditary angio-oedema. Lancet (London, England). 2012;379(9814):474–81.CrossRefGoogle Scholar
  10. 10.
    Pappalardo E, Cicardi M, Duponchel C, Carugati A, Choquet S, Agostoni A, Tosi M. Frequent de novo mutations and exon deletions in the C1inhibitor gene of patients with angioedema. J Allergy Clin Immunol. 2000;106(6):1147–54.CrossRefGoogle Scholar
  11. 11.
    Farkas H, Martinez-Saguer I, Bork K, Bowen T, Craig T, Frank M, Germenis AE, Grumach AS, Luczay A, Varga L, Zanichelli A. International consensus on the diagnosis and management of pediatric patients with hereditary angioedema with C1 inhibitor deficiency. Allergy. 2017;72(2):300–13.CrossRefGoogle Scholar
  12. 12.
    MacGinnitie AJ. Pediatric hereditary angioedema. Pediatr Allergy Immunol. 2014;25(5):420–7.CrossRefGoogle Scholar
  13. 13.
    Khan DA. Hereditary angioedema: historical aspects, classification, pathophysiology, clinical presentation, and laboratory diagnosis. Allergy Asthma Proc. 2011;32(1):1–10.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Section of Pulmonary/Critical Care & Allergy/Immunology, LSU Health New OrleansNew OrleansUSA
  2. 2.Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN)New OrleansUSA

Personalised recommendations